Last reviewed · How we verify
NCT02635048
Mini-PCNL Versus Standard-PCNL For The Management of 20-40 mm Size Kidney Stones
NA trial testing Mini Percutaneous Nephrolithotomy in Kidney Calculi in 1,980 participants. Completed in 20 August 2019.
1 August 2019
Quick facts
| Lead sponsor | The First Affiliated Hospital of Guangzhou Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,980 |
| Start date | 1 January 2016 |
| Primary completion | 1 August 2019 |
| Estimated completion | 20 August 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Mini Percutaneous Nephrolithotomy
- Percutaneous Nephrolithotomy
Conditions studied
- Kidney Calculi — all drugs for Kidney Calculi →
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Who can join
Adults 18 to 70, any sex, with Kidney Calculi. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Percutaneous nephrolithotomy (PCNL) has been considered as the first-line choice for the management of \>20mm kidney stones. The traditional nephrostomy tract of PNL was dilated to 24-30F, which is referred to as "Standard-PCNL". Standard PNL has an ideal stones free rate (SFR), however, at the cost of severe morbidity. To decrease the disadvantages related to standard PNL, "mini-perc" or "mini-PCNL", 20F or less, was first introduced to pediatric procedure in 1997, and subsequently implemented in adults with the expectation of similar SFR and low morbidity in the past twenty years. Although abundant efforts have been done, whether mini-perc outweigh standard-PNL for the treatment of \>20mm calculis in terms of efficiency and safety remains controversial. To solve this problem, we performed this multicenter, parallel, open-label randomized controlled trial (RCT).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02635048
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mini Percutaneous Nephrolithotomy
Trials testing the same drug.
- NCT07464717 — Standard Versus Mini Percutaneous Nephrolithotomy for Renal Stones · NA · completed
- NCT07349992 — Retrograde Intrarenal Surgery (RIRS) With High-Power Laser and Flexible, Navigable Suction Access Sheath (FANS) vs Mini- · NA · completed
- NCT05911945 — Failed Insertion of Ureteral Access Sheath During Flexible Ureterorenoscopy · NA · completed
Other recruiting trials for Kidney Calculi
Currently open trials in the same condition.
- NCT06989320 — Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease · NA · recruiting
- NCT06667557 — Comparing Super Pulse Fiber Thulium Laser and Holmium Laser for Ureteral Stone Fragmentation During Ureteroscopy · recruiting
- NCT07238803 — Outcomes of Using FANS With FURS in TTT of Lower Calyceal Stones. · NA · recruiting
- NCT06684756 — Comparison of Vacuum-Assisted and Conventional Ureteral Access Sheath in Retrograde Intrarenal Surgery · NA · active not recruiting
- NCT06331546 — Gut Oxalate Absorption in Calcium Oxalate Stone Disease · NA · recruiting
Other The First Affiliated Hospital of Guangzhou Medical University trials
Trials by the same sponsor.
- NCT07413952 — Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases · Phase 2 · not yet recruiting
- NCT07395375 — Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection · NA · not yet recruiting
- NCT07395362 — Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules · NA · not yet recruiting
- NCT07395349 — Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection · NA · not yet recruiting
- NCT07377916 — Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02635048 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Guangzhou Medical University
- Last refreshed: 5 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02635048.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing